| Author . | Intervention Group . | Patient, No. (%) . | Mean or Median Age (±SD or IQR), y . | Men, No. (%) . | ICU Admission, No. (%) . | Transplant Recipients, No. (%) . | Immunosuppressant User, No. (%) . | ESRD on Hemodialysis, No. (%) . | Intravascular Device, No. (%) . | Effective Empirical Therapy, No. (%) . | Days of Treatment, Median (IQR) . | Days of Hospital Stay, Median (IQR) . | Mortality, No. (%) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amipara et al. [7] | All patients | 766 (100) | 67 (55–79) | 328 (43) | ND | ND | ND | 77 (10)a | 116 (15)b | 710 (93) | ND | ND | 69 (9) |
| FUBC | 219 (29) | 65 (52–75) | 96 (44) | ND | ND | ND | 55 (25)a | 60 (27)b | 204 (93) | ND | ND | 12 (5) | |
| No FUBC | 547 (71) | 68 (56–79) | 232 (42) | ND | ND | ND | 22 (4)a | 56 (10)b | 506 (93) | ND | ND | 57 (10) | |
| Chan et al. [19] | All patients | 335 (100) | ND | 186 (56) | ND | ND | ND | ND | ND | ND | ND | ND | 32 (10) |
| FUBC | 299 (89) | 60 (48–71) | 174 (58) | ND | ND | ND | ND | ND | ND | ND | 8 (5–18) | 27 (9) | |
| No FUBC | 36 (11) | 64 (53–72) | 12 (33) | ND | ND | ND | ND | ND | ND | ND | 4 (3–9) | 5 (14) | |
| Elamin et al. [11] | All patients | 482 (100) | ND | ND | 174 (36) | ND | ND | ND | ND | ND | ND | ND | 13 (3) |
| FUBC | 321 (67) | ND | ND | 133 (41) | ND | ND | ND | ND | ND | 14 (10–14) | 7 (5–11) | 9 (3) | |
| No FUBC | 161 (33) | ND | ND | 41 (26) | ND | ND | ND | ND | ND | 11 (10–14) | 5 (4–7) | 4 (3) | |
| Giannella et al. [9] | All patients | 1576 (100) | 69 (17) | 878 (56) | 126 (8) | ND | 332 (21)c | ND | ND | 1075 (68) | 11 (7–15) | 12 (7–22) | 164 (10) |
| FUBC | 278 (18) | 62 (16) | 171 (62) | 53 (19) | ND | 89 (32)c | ND | ND | 170 (61) | 15 (10–21) | 21 (13–36) | 38 (14) | |
| No FUBC | 1298 (82) | 70 (16) | 707 (55) | 73 (6) | ND | 243 (19)c | ND | ND | 905 (70) | 10 (7–14) | 11 (7–19) | 126 (10) | |
| Green et al. [16] | All patients | 159 (100) | 57 (16) | 94 (59) | 73 (45) | ND | ND | 31 (20) | 94 (59)b | ND | ND | ND | 40 (25) |
| FUBC | 127 (80) | 57 (17) | 76 (60) | 60 (46) | ND | ND | 23 (18) | 77 (61)b | ND | ND | ND | 24 (19) | |
| No FUBC | 32 (20) | 59 (15) | 18 (56) | 13 (41) | ND | ND | 8 (25) | 17 (53)b | ND | ND | ND | 16 (50) | |
| Jung et al. [17] | All patients | 1481 (100) | 69 (14) | 745 (50) | ND | 68 (5)d | 92 (6)e | 43 (3)f | 327 (22) | ND | ND | ND | 105 (7) |
| FUBC | 1276 (86) | 69 (14) | 628 (49) | ND | 62 (5)d | 89 (7)e | 41 (3)f | 308 (24) | 1050 (82) | ND | ND | 87 (7) | |
| No FUBC | 205 (14) | 69 (14) | 117 (57) | ND | 6 (3)d | 3 (1)e | 2 (1)f | 19 (9) | ND | ND | ND | 18 (9) | |
| Maskarinec et al. [8] | All patients | 1702 (100) | 61 (ND) | 936 (55) | 64 (4) | 232 (14)g | 411 (24)e | 172 (10) | ND | 1075 (63)h | ND | ND | 284 (17)i |
| FUBC | 1164 (68) | 60 (16) | 632 (54) | 41 (4) | 188 (16)g | 305 (26)e | 135 (12) | ND | 729 (63)h | 15 (13–19) | ND | 176 (15)ji | |
| No FUBC | 538 (32) | 62 (16) | 304 (57) | 23 (4) | 44 (8)g | 106 (20)e | 37 (7) | ND | 346 (64)h | 13 (8–16) | ND | 108 (20) i | |
| Mitaka et al. [10] | All patients | 376 (100) | ND | 174 (46) | 138 (37) | ND | ND | 43 (11) | 115 (31) | ND | ND | ND | ND |
| FUBC | 271 (72) | 69 (59–82) | 123 (45) | 110 (40) | ND | ND | 37 (14) | 93 (34) | ND | 8 (5.5–13)j | 9 (6–14)j | 4 (5)j | |
| No FUBC | 105 (28) | 73 (64–83) | 51 (49) | 28 (27) | ND | ND | 6 (6) | 22 (21) | ND | 6 (4–10)j | 7 (4.5–10.5)ij | 10 (11)ij | |
| Wiggers et al. [18] | All patients | 901 (100) | 67 (18) | 408 (45) | 240 (27) | ND | ND | ND | ND | ND | ND | 14 (5–33) | 131 (15)k |
| FUBC | 241 (27) | 62 (18) | 94 (39) | 96 (40) | ND | ND | ND | ND | ND | ND | 24 (11–46) | 35 (15)k | |
| No FUBC | 660 (73) | 69 (18) | 314 (48) | 144 (22) | ND | ND | ND | ND | ND | ND | 10 (4–29) | 96 (15)k |
| Author . | Intervention Group . | Patient, No. (%) . | Mean or Median Age (±SD or IQR), y . | Men, No. (%) . | ICU Admission, No. (%) . | Transplant Recipients, No. (%) . | Immunosuppressant User, No. (%) . | ESRD on Hemodialysis, No. (%) . | Intravascular Device, No. (%) . | Effective Empirical Therapy, No. (%) . | Days of Treatment, Median (IQR) . | Days of Hospital Stay, Median (IQR) . | Mortality, No. (%) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amipara et al. [7] | All patients | 766 (100) | 67 (55–79) | 328 (43) | ND | ND | ND | 77 (10)a | 116 (15)b | 710 (93) | ND | ND | 69 (9) |
| FUBC | 219 (29) | 65 (52–75) | 96 (44) | ND | ND | ND | 55 (25)a | 60 (27)b | 204 (93) | ND | ND | 12 (5) | |
| No FUBC | 547 (71) | 68 (56–79) | 232 (42) | ND | ND | ND | 22 (4)a | 56 (10)b | 506 (93) | ND | ND | 57 (10) | |
| Chan et al. [19] | All patients | 335 (100) | ND | 186 (56) | ND | ND | ND | ND | ND | ND | ND | ND | 32 (10) |
| FUBC | 299 (89) | 60 (48–71) | 174 (58) | ND | ND | ND | ND | ND | ND | ND | 8 (5–18) | 27 (9) | |
| No FUBC | 36 (11) | 64 (53–72) | 12 (33) | ND | ND | ND | ND | ND | ND | ND | 4 (3–9) | 5 (14) | |
| Elamin et al. [11] | All patients | 482 (100) | ND | ND | 174 (36) | ND | ND | ND | ND | ND | ND | ND | 13 (3) |
| FUBC | 321 (67) | ND | ND | 133 (41) | ND | ND | ND | ND | ND | 14 (10–14) | 7 (5–11) | 9 (3) | |
| No FUBC | 161 (33) | ND | ND | 41 (26) | ND | ND | ND | ND | ND | 11 (10–14) | 5 (4–7) | 4 (3) | |
| Giannella et al. [9] | All patients | 1576 (100) | 69 (17) | 878 (56) | 126 (8) | ND | 332 (21)c | ND | ND | 1075 (68) | 11 (7–15) | 12 (7–22) | 164 (10) |
| FUBC | 278 (18) | 62 (16) | 171 (62) | 53 (19) | ND | 89 (32)c | ND | ND | 170 (61) | 15 (10–21) | 21 (13–36) | 38 (14) | |
| No FUBC | 1298 (82) | 70 (16) | 707 (55) | 73 (6) | ND | 243 (19)c | ND | ND | 905 (70) | 10 (7–14) | 11 (7–19) | 126 (10) | |
| Green et al. [16] | All patients | 159 (100) | 57 (16) | 94 (59) | 73 (45) | ND | ND | 31 (20) | 94 (59)b | ND | ND | ND | 40 (25) |
| FUBC | 127 (80) | 57 (17) | 76 (60) | 60 (46) | ND | ND | 23 (18) | 77 (61)b | ND | ND | ND | 24 (19) | |
| No FUBC | 32 (20) | 59 (15) | 18 (56) | 13 (41) | ND | ND | 8 (25) | 17 (53)b | ND | ND | ND | 16 (50) | |
| Jung et al. [17] | All patients | 1481 (100) | 69 (14) | 745 (50) | ND | 68 (5)d | 92 (6)e | 43 (3)f | 327 (22) | ND | ND | ND | 105 (7) |
| FUBC | 1276 (86) | 69 (14) | 628 (49) | ND | 62 (5)d | 89 (7)e | 41 (3)f | 308 (24) | 1050 (82) | ND | ND | 87 (7) | |
| No FUBC | 205 (14) | 69 (14) | 117 (57) | ND | 6 (3)d | 3 (1)e | 2 (1)f | 19 (9) | ND | ND | ND | 18 (9) | |
| Maskarinec et al. [8] | All patients | 1702 (100) | 61 (ND) | 936 (55) | 64 (4) | 232 (14)g | 411 (24)e | 172 (10) | ND | 1075 (63)h | ND | ND | 284 (17)i |
| FUBC | 1164 (68) | 60 (16) | 632 (54) | 41 (4) | 188 (16)g | 305 (26)e | 135 (12) | ND | 729 (63)h | 15 (13–19) | ND | 176 (15)ji | |
| No FUBC | 538 (32) | 62 (16) | 304 (57) | 23 (4) | 44 (8)g | 106 (20)e | 37 (7) | ND | 346 (64)h | 13 (8–16) | ND | 108 (20) i | |
| Mitaka et al. [10] | All patients | 376 (100) | ND | 174 (46) | 138 (37) | ND | ND | 43 (11) | 115 (31) | ND | ND | ND | ND |
| FUBC | 271 (72) | 69 (59–82) | 123 (45) | 110 (40) | ND | ND | 37 (14) | 93 (34) | ND | 8 (5.5–13)j | 9 (6–14)j | 4 (5)j | |
| No FUBC | 105 (28) | 73 (64–83) | 51 (49) | 28 (27) | ND | ND | 6 (6) | 22 (21) | ND | 6 (4–10)j | 7 (4.5–10.5)ij | 10 (11)ij | |
| Wiggers et al. [18] | All patients | 901 (100) | 67 (18) | 408 (45) | 240 (27) | ND | ND | ND | ND | ND | ND | 14 (5–33) | 131 (15)k |
| FUBC | 241 (27) | 62 (18) | 94 (39) | 96 (40) | ND | ND | ND | ND | ND | ND | 24 (11–46) | 35 (15)k | |
| No FUBC | 660 (73) | 69 (18) | 314 (48) | 144 (22) | ND | ND | ND | ND | ND | ND | 10 (4–29) | 96 (15)k |
Abbreviations: ESRD, end-stage renal disease; FUBCs, follow-up blood cultures; ICU, intensive care unit; IQR, interquartile range; ND, no date.
Patients with ESRD. No data existed on whether all these patients received dialysis.
Central venous catheter.
No details of immunosuppressants were given in the article.
The number (%) of patients with solid organ transplantation was 39 (3) in the whole study population, 34 (3) in patients with FUBCs, and 5 (2) in patients without FUBCs. The number (%) of patients with bone marrow transplantation was 29 (2) in the whole study population, 28 (2) in patients with FUBCs, and 1 (<1) in patients without FUBCs.
Steroid use.
The number (%) of patients who received hemodialysis was 37 (2) in the whole study population, 35 (3) in patients with FUBCs, and 2 (1) in patients without FUBCs. The number (%) of patients who received peritoneal dialysis was 6 (<1) in the whole study population, 6 (<1) in patients with FUBCs, and 0 (0) in patients without FUBCs. These data were extracted from the individual patient data.
There was no mention of specific transplant details (eg, solid organ transplant or bone marrow transplant).
The original article mentioned “days to effective therapy: 0 days.”
The number (%) of deaths from attributable causes was 176 (10) in the whole study population, 98 (8) in patients with FUBCs, and 78 (15) in patients without FUBCs.
Only data after propensity score matching were presented.
The number (%) of deaths in the hospital was 193 (21) in the whole study population, 54 (22) in patients with FUBCs, and 139 (21) in patients without FUBCs.
| Author . | Intervention Group . | Patient, No. (%) . | Mean or Median Age (±SD or IQR), y . | Men, No. (%) . | ICU Admission, No. (%) . | Transplant Recipients, No. (%) . | Immunosuppressant User, No. (%) . | ESRD on Hemodialysis, No. (%) . | Intravascular Device, No. (%) . | Effective Empirical Therapy, No. (%) . | Days of Treatment, Median (IQR) . | Days of Hospital Stay, Median (IQR) . | Mortality, No. (%) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amipara et al. [7] | All patients | 766 (100) | 67 (55–79) | 328 (43) | ND | ND | ND | 77 (10)a | 116 (15)b | 710 (93) | ND | ND | 69 (9) |
| FUBC | 219 (29) | 65 (52–75) | 96 (44) | ND | ND | ND | 55 (25)a | 60 (27)b | 204 (93) | ND | ND | 12 (5) | |
| No FUBC | 547 (71) | 68 (56–79) | 232 (42) | ND | ND | ND | 22 (4)a | 56 (10)b | 506 (93) | ND | ND | 57 (10) | |
| Chan et al. [19] | All patients | 335 (100) | ND | 186 (56) | ND | ND | ND | ND | ND | ND | ND | ND | 32 (10) |
| FUBC | 299 (89) | 60 (48–71) | 174 (58) | ND | ND | ND | ND | ND | ND | ND | 8 (5–18) | 27 (9) | |
| No FUBC | 36 (11) | 64 (53–72) | 12 (33) | ND | ND | ND | ND | ND | ND | ND | 4 (3–9) | 5 (14) | |
| Elamin et al. [11] | All patients | 482 (100) | ND | ND | 174 (36) | ND | ND | ND | ND | ND | ND | ND | 13 (3) |
| FUBC | 321 (67) | ND | ND | 133 (41) | ND | ND | ND | ND | ND | 14 (10–14) | 7 (5–11) | 9 (3) | |
| No FUBC | 161 (33) | ND | ND | 41 (26) | ND | ND | ND | ND | ND | 11 (10–14) | 5 (4–7) | 4 (3) | |
| Giannella et al. [9] | All patients | 1576 (100) | 69 (17) | 878 (56) | 126 (8) | ND | 332 (21)c | ND | ND | 1075 (68) | 11 (7–15) | 12 (7–22) | 164 (10) |
| FUBC | 278 (18) | 62 (16) | 171 (62) | 53 (19) | ND | 89 (32)c | ND | ND | 170 (61) | 15 (10–21) | 21 (13–36) | 38 (14) | |
| No FUBC | 1298 (82) | 70 (16) | 707 (55) | 73 (6) | ND | 243 (19)c | ND | ND | 905 (70) | 10 (7–14) | 11 (7–19) | 126 (10) | |
| Green et al. [16] | All patients | 159 (100) | 57 (16) | 94 (59) | 73 (45) | ND | ND | 31 (20) | 94 (59)b | ND | ND | ND | 40 (25) |
| FUBC | 127 (80) | 57 (17) | 76 (60) | 60 (46) | ND | ND | 23 (18) | 77 (61)b | ND | ND | ND | 24 (19) | |
| No FUBC | 32 (20) | 59 (15) | 18 (56) | 13 (41) | ND | ND | 8 (25) | 17 (53)b | ND | ND | ND | 16 (50) | |
| Jung et al. [17] | All patients | 1481 (100) | 69 (14) | 745 (50) | ND | 68 (5)d | 92 (6)e | 43 (3)f | 327 (22) | ND | ND | ND | 105 (7) |
| FUBC | 1276 (86) | 69 (14) | 628 (49) | ND | 62 (5)d | 89 (7)e | 41 (3)f | 308 (24) | 1050 (82) | ND | ND | 87 (7) | |
| No FUBC | 205 (14) | 69 (14) | 117 (57) | ND | 6 (3)d | 3 (1)e | 2 (1)f | 19 (9) | ND | ND | ND | 18 (9) | |
| Maskarinec et al. [8] | All patients | 1702 (100) | 61 (ND) | 936 (55) | 64 (4) | 232 (14)g | 411 (24)e | 172 (10) | ND | 1075 (63)h | ND | ND | 284 (17)i |
| FUBC | 1164 (68) | 60 (16) | 632 (54) | 41 (4) | 188 (16)g | 305 (26)e | 135 (12) | ND | 729 (63)h | 15 (13–19) | ND | 176 (15)ji | |
| No FUBC | 538 (32) | 62 (16) | 304 (57) | 23 (4) | 44 (8)g | 106 (20)e | 37 (7) | ND | 346 (64)h | 13 (8–16) | ND | 108 (20) i | |
| Mitaka et al. [10] | All patients | 376 (100) | ND | 174 (46) | 138 (37) | ND | ND | 43 (11) | 115 (31) | ND | ND | ND | ND |
| FUBC | 271 (72) | 69 (59–82) | 123 (45) | 110 (40) | ND | ND | 37 (14) | 93 (34) | ND | 8 (5.5–13)j | 9 (6–14)j | 4 (5)j | |
| No FUBC | 105 (28) | 73 (64–83) | 51 (49) | 28 (27) | ND | ND | 6 (6) | 22 (21) | ND | 6 (4–10)j | 7 (4.5–10.5)ij | 10 (11)ij | |
| Wiggers et al. [18] | All patients | 901 (100) | 67 (18) | 408 (45) | 240 (27) | ND | ND | ND | ND | ND | ND | 14 (5–33) | 131 (15)k |
| FUBC | 241 (27) | 62 (18) | 94 (39) | 96 (40) | ND | ND | ND | ND | ND | ND | 24 (11–46) | 35 (15)k | |
| No FUBC | 660 (73) | 69 (18) | 314 (48) | 144 (22) | ND | ND | ND | ND | ND | ND | 10 (4–29) | 96 (15)k |
| Author . | Intervention Group . | Patient, No. (%) . | Mean or Median Age (±SD or IQR), y . | Men, No. (%) . | ICU Admission, No. (%) . | Transplant Recipients, No. (%) . | Immunosuppressant User, No. (%) . | ESRD on Hemodialysis, No. (%) . | Intravascular Device, No. (%) . | Effective Empirical Therapy, No. (%) . | Days of Treatment, Median (IQR) . | Days of Hospital Stay, Median (IQR) . | Mortality, No. (%) . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amipara et al. [7] | All patients | 766 (100) | 67 (55–79) | 328 (43) | ND | ND | ND | 77 (10)a | 116 (15)b | 710 (93) | ND | ND | 69 (9) |
| FUBC | 219 (29) | 65 (52–75) | 96 (44) | ND | ND | ND | 55 (25)a | 60 (27)b | 204 (93) | ND | ND | 12 (5) | |
| No FUBC | 547 (71) | 68 (56–79) | 232 (42) | ND | ND | ND | 22 (4)a | 56 (10)b | 506 (93) | ND | ND | 57 (10) | |
| Chan et al. [19] | All patients | 335 (100) | ND | 186 (56) | ND | ND | ND | ND | ND | ND | ND | ND | 32 (10) |
| FUBC | 299 (89) | 60 (48–71) | 174 (58) | ND | ND | ND | ND | ND | ND | ND | 8 (5–18) | 27 (9) | |
| No FUBC | 36 (11) | 64 (53–72) | 12 (33) | ND | ND | ND | ND | ND | ND | ND | 4 (3–9) | 5 (14) | |
| Elamin et al. [11] | All patients | 482 (100) | ND | ND | 174 (36) | ND | ND | ND | ND | ND | ND | ND | 13 (3) |
| FUBC | 321 (67) | ND | ND | 133 (41) | ND | ND | ND | ND | ND | 14 (10–14) | 7 (5–11) | 9 (3) | |
| No FUBC | 161 (33) | ND | ND | 41 (26) | ND | ND | ND | ND | ND | 11 (10–14) | 5 (4–7) | 4 (3) | |
| Giannella et al. [9] | All patients | 1576 (100) | 69 (17) | 878 (56) | 126 (8) | ND | 332 (21)c | ND | ND | 1075 (68) | 11 (7–15) | 12 (7–22) | 164 (10) |
| FUBC | 278 (18) | 62 (16) | 171 (62) | 53 (19) | ND | 89 (32)c | ND | ND | 170 (61) | 15 (10–21) | 21 (13–36) | 38 (14) | |
| No FUBC | 1298 (82) | 70 (16) | 707 (55) | 73 (6) | ND | 243 (19)c | ND | ND | 905 (70) | 10 (7–14) | 11 (7–19) | 126 (10) | |
| Green et al. [16] | All patients | 159 (100) | 57 (16) | 94 (59) | 73 (45) | ND | ND | 31 (20) | 94 (59)b | ND | ND | ND | 40 (25) |
| FUBC | 127 (80) | 57 (17) | 76 (60) | 60 (46) | ND | ND | 23 (18) | 77 (61)b | ND | ND | ND | 24 (19) | |
| No FUBC | 32 (20) | 59 (15) | 18 (56) | 13 (41) | ND | ND | 8 (25) | 17 (53)b | ND | ND | ND | 16 (50) | |
| Jung et al. [17] | All patients | 1481 (100) | 69 (14) | 745 (50) | ND | 68 (5)d | 92 (6)e | 43 (3)f | 327 (22) | ND | ND | ND | 105 (7) |
| FUBC | 1276 (86) | 69 (14) | 628 (49) | ND | 62 (5)d | 89 (7)e | 41 (3)f | 308 (24) | 1050 (82) | ND | ND | 87 (7) | |
| No FUBC | 205 (14) | 69 (14) | 117 (57) | ND | 6 (3)d | 3 (1)e | 2 (1)f | 19 (9) | ND | ND | ND | 18 (9) | |
| Maskarinec et al. [8] | All patients | 1702 (100) | 61 (ND) | 936 (55) | 64 (4) | 232 (14)g | 411 (24)e | 172 (10) | ND | 1075 (63)h | ND | ND | 284 (17)i |
| FUBC | 1164 (68) | 60 (16) | 632 (54) | 41 (4) | 188 (16)g | 305 (26)e | 135 (12) | ND | 729 (63)h | 15 (13–19) | ND | 176 (15)ji | |
| No FUBC | 538 (32) | 62 (16) | 304 (57) | 23 (4) | 44 (8)g | 106 (20)e | 37 (7) | ND | 346 (64)h | 13 (8–16) | ND | 108 (20) i | |
| Mitaka et al. [10] | All patients | 376 (100) | ND | 174 (46) | 138 (37) | ND | ND | 43 (11) | 115 (31) | ND | ND | ND | ND |
| FUBC | 271 (72) | 69 (59–82) | 123 (45) | 110 (40) | ND | ND | 37 (14) | 93 (34) | ND | 8 (5.5–13)j | 9 (6–14)j | 4 (5)j | |
| No FUBC | 105 (28) | 73 (64–83) | 51 (49) | 28 (27) | ND | ND | 6 (6) | 22 (21) | ND | 6 (4–10)j | 7 (4.5–10.5)ij | 10 (11)ij | |
| Wiggers et al. [18] | All patients | 901 (100) | 67 (18) | 408 (45) | 240 (27) | ND | ND | ND | ND | ND | ND | 14 (5–33) | 131 (15)k |
| FUBC | 241 (27) | 62 (18) | 94 (39) | 96 (40) | ND | ND | ND | ND | ND | ND | 24 (11–46) | 35 (15)k | |
| No FUBC | 660 (73) | 69 (18) | 314 (48) | 144 (22) | ND | ND | ND | ND | ND | ND | 10 (4–29) | 96 (15)k |
Abbreviations: ESRD, end-stage renal disease; FUBCs, follow-up blood cultures; ICU, intensive care unit; IQR, interquartile range; ND, no date.
Patients with ESRD. No data existed on whether all these patients received dialysis.
Central venous catheter.
No details of immunosuppressants were given in the article.
The number (%) of patients with solid organ transplantation was 39 (3) in the whole study population, 34 (3) in patients with FUBCs, and 5 (2) in patients without FUBCs. The number (%) of patients with bone marrow transplantation was 29 (2) in the whole study population, 28 (2) in patients with FUBCs, and 1 (<1) in patients without FUBCs.
Steroid use.
The number (%) of patients who received hemodialysis was 37 (2) in the whole study population, 35 (3) in patients with FUBCs, and 2 (1) in patients without FUBCs. The number (%) of patients who received peritoneal dialysis was 6 (<1) in the whole study population, 6 (<1) in patients with FUBCs, and 0 (0) in patients without FUBCs. These data were extracted from the individual patient data.
There was no mention of specific transplant details (eg, solid organ transplant or bone marrow transplant).
The original article mentioned “days to effective therapy: 0 days.”
The number (%) of deaths from attributable causes was 176 (10) in the whole study population, 98 (8) in patients with FUBCs, and 78 (15) in patients without FUBCs.
Only data after propensity score matching were presented.
The number (%) of deaths in the hospital was 193 (21) in the whole study population, 54 (22) in patients with FUBCs, and 139 (21) in patients without FUBCs.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
